Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Want to cut your energy bills? Here’s how five experts are doing it 
PARSIPPANY, N.J., March 08, 2016 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574 [email protected]
